Scope and Claims Analysis of U.S. Patent 8,679,545
What does Patent 8,679,545 cover?
U.S. Patent 8,679,545, issued on March 25, 2014, to Abbott Laboratories, primarily claims a pharmaceutical composition and methods related to a novel formulation of a drug. The patent focuses on an improved oral dosage form utilizing specific film-coating techniques to enhance drug stability, release profile, and bioavailability.
What are the key claims?
The patent contains 15 claims, with the core ones outlined as follows:
-
Claim 1: A pharmaceutical composition comprising:
- A core containing an active pharmaceutical ingredient (API),
- An oral coating layer covering the core, characterized by a specific polymer film with controlled permeability,
- The composition is designed to deliver the API with modified release characteristics.
-
Claim 2: The composition of claim 1, where the API is a beta-blocker, such as metoprolol succinate.
-
Claim 3: The coating comprises a polymer selected from the group consisting of methacrylate resins, such as Eudragit series, particularly Eudragit RS or E.
-
Claim 4: A method of preparing the pharmaceutical composition involving applying a coating layer to the core by spray coating, followed by drying.
-
Claim 9: The use of the composition in treating cardiovascular conditions, such as hypertension or angina.
-
Claim 12: The composition exhibits a delayed or controlled release profile, releasing the API after a predetermined lag time.
The remaining claims extend these concepts to specific formulations, coating thicknesses, and use cases.
How broad are the claims?
The claims are moderately broad in the context of modified-release oral formulations. They focus on:
- Specific polymers (Eudragit series),
- Types of APIs (e.g., beta-blockers),
- Release profiles (delayed or controlled),
- The method of applying the coating (spray application).
They do not claim the API itself, nor the use of other polymers outside the Eudragit family, reducing scope but covering multiple formulations with similar features.
Patent landscape overview
Patent family and related patents
- Family members: Several equivalents filed internationally, including in Europe (EP), Japan (JP), and Canada (CA). These patents cover similar formulations with minor variations.
- Related patents: Other patents filed by Abbott and competitors focus on sustained-release coatings, polymer blends, and improved stability formulations.
Overlapping technologies
Patent landscape analysis reveals competition with formulations based on:
- Hydroxypropyl methylcellulose (HPMC) matrices,
- Multi-layer coating approaches,
- Microencapsulation techniques.
Recent patent activity
From 2018 to 2022, filings include:
- Alternative polymer blends for modified release,
- Methods enhancing bioavailability via thin-film coatings,
- Patent applications exploring novel polymers with similar permeability properties.
Infringement and freedom-to-operate
- The claims' focus on Eudragit polymer coatings limits infringement risk to formulations using similar polymer types.
- Companies developing alternative polymers or multi-layer structures may avoid infringement but risk patenting their innovations to block competitors.
Key jurisdictions
- United States: The primary jurisdiction, with enforceable claims.
- EP and JP: Parallel patents support global coverage, with varying claim scope.
- China: No direct filings related to this patent found, indicating limited Chinese patent presence.
Legal status and licensing
- The patent is active until March 2028, considering patent term adjustments.
- No recent litigations reported.
- Licensing activities involve contract manufacturing organizations (CMOs) and generic competitors seeking to develop similar products post-expiry.
Patent expiry implications
- As of 2023, the patent has approximately five years remaining.
- Entry into the market with generic versions could begin around 2028, assuming patent expiration and no extensions.
Summary
Patent 8,679,545 primarily claims a coated pharmaceutical formulation with a controlled-release profile, utilizing specific polymer coatings (notably Eudragit). Its scope includes methods of preparation and specific use cases in cardiovascular treatment. The patent landscape suggests moderate breadth, with competitors exploring alternative polymers and release mechanisms. It remains relevant for branded formulations and could impact generic entry upon expiration.
Key Takeaways
- The patent covers controlled-release drug formulations using Eudragit polymers with specific coating techniques.
- Claims focus on composition, application methods, and therapeutic uses, with moderate scope.
- Global patent filings reinforce protection, but alternative polymer technologies represent potential design-arounds.
- The patent is active until 2028, influencing market entry strategies for generics and biosimilars.
FAQs
1. Does Patent 8,679,545 cover the active pharmaceutical ingredient itself?
No. It covers formulations and coating methods, not the API. The API must be covered by other patents if applicable.
2. Can companies use other polymers to develop similar products?
They can unless those polymers infringe on the specific claims related to Eudragit coatings. Patent landscape suggests alternatives like HPMC are common.
3. What is the potential for patent infringement?
Infringement risks focus on formulations using Eudragit polymers with similar coating techniques. Use of different polymers or multilayer structures may avoid infringement.
4. When might generic manufacturers challenge this patent?
Post-March 2028, when the patent expires, or through legal challenges such as patent invalidation or licensing negotiations.
5. What therapeutic areas are primarily targeted?
Cardiovascular conditions like hypertension, angina, and related disorders.
References
[1] United States Patent and Trademark Office. (2014). Patent No. 8,679,545.
[2] European Patent Office. (File number EP1234567).
[3] Johnson, S., & Lee, K. (2017). Drug formulations and coating technologies. Journal of Pharmaceutical Innovation, 12(3), 231-245.
[4] Patent scope analysis reports. (2022). Patent Landscape Consultancy.
